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The human immunodeficiency virus type 1 (HIV-1)
envelope glycoprotein is composed of a complex be-
tween the surface subunit gp120, which binds to cellular
receptors, and the transmembrane subunit gp41. Upon
activation of the envelope glycoprotein by cellular re-
ceptors, gp41 undergoes conformational changes that
mediate fusion of the viral and cellular membranes.
Prior to formation of a fusogenic “trimer-of-hairpins”
structure, gp41 transiently adopts a prefusogenic con-
formation whose structural features are poorly under-
stood. An important approach toward understanding
structural conformations of gp41 during HIV-1 entry has
been to analyze the structural targets of gp41 inhibitors.
We have constructed epitope-tagged versions of 5-Helix,
a designed protein that binds to the C-peptide region of
gp41 and inhibits HIV-1 membrane fusion. Using these
5-Helix variants, we examined which conformation of
gp41 is the target of 5-Helix. We find that although 5-He-
lix binds poorly to native gp41, it binds strongly to gp41
activated by interaction of the envelope protein with
either soluble CD4 or membrane-bound cellular recep-
tors. This preferential interaction with activated gp41
results in the accumulation of 5-Helix on the surface of
activated cells. These results strongly suggest that the
gp41 prefusogenic intermediate is the target of 5-Helix
and that this intermediate has a remarkably “open”
structure, with exposed C-peptide regions. These results
provide important structural information about this in-
termediate that should facilitate the development of
HIV-1 entry inhibitors and may lead to new vaccine
strategies.
Entry of the human immunodeficiency virus type 1 (HIV-1)1
into host cells is mediated by its envelope glycoprotein, a com-
plex of the receptor-binding subunit gp120 and the transmem-
brane subunit gp41 (1). gp41 possesses membrane fusion ac-
tivity and contains an N-terminal fusion peptide followed by
two heptad repeat regions termed the N-peptide region and the
C-peptide region (see Fig. 1a) (1, 2). Upon binding of gp120 to
its cellular receptors, CD4 and certain chemokine co-receptors,
gp41 undergoes a multi-step structural transition from a na-
tive, nonfusogenic conformation to a fusion-active conformation
(3–7).
The presumed fusion-active conformation of gp41 is a com-
plex of three helical hairpins, in which each hairpin is formed
from an N-peptide helix and an anti-parallel C-peptide helix
(see Fig. 1b) (8–12). This “trimer-of-hairpins” structure is a
six-helix bundle consisting of an internal triple-stranded
coiled-coil (three N-peptide helices) with three outer C-peptide
helices packed along hydrophobic grooves. In this conforma-
tion, the fusion peptide and the transmembrane segment are
placed in closed proximity, providing a plausible mechanism for
apposition of the target and viral membranes (2, 9).
Synthetic C-peptides potently inhibit gp41-mediated mem-
brane fusion (13–15), and one of these, DP178, binds to a
conformation of gp41 activated by interaction of envelope pro-
tein with cellular receptors (5). These peptide inhibitors are
unlikely to target the trimer-of-hairpins structure, because of
its extreme stability and the high effective concentrations of
the N- and C-peptide regions within a hairpin. These observa-
tions suggest that native gp41 converts to a transiently popu-
lated “prehairpin” intermediate prior to formation of the fuso-
genic trimer-of-hairpins structure (see Fig. 6) (2). Other entry
inhibitors, such as IQN17 (16), N(CCG)-gp41 (17), N36Mut(e,g)
(18), and 5-Helix (19), may also bind this intermediate, al-
though there is no direct evidence for this hypothesis. An
understanding of the structural features of this prefusogenic
intermediate is critical because it appears to be an attractive
drug target (15, 20). Indeed, clinical trials have demonstrated
the efficacy of the C-peptide DP178 (also called T-20) in reduc-
ing viral titers in HIV-1-infected patients (21, 22).
5-Helix is a designed, recombinant protein (see Fig. 1, c and
d) that consists of three N-peptide regions and two C-peptide
regions (19). This protein is thought to bind the C-peptide
region of gp41 and potently inhibits the fusogenic activity of
gp41 at nanomolar concentrations. However, it is unknown
which conformation of gp41 is the target of 5-Helix. In this
study, we designed a tagged 5-Helix protein containing the Myc
epitope (EQKLISEEDL) and investigated the target of 5-Helix
using a surface co-immunoprecipitation assay. Our results
show that 5-Helix binds to HIV-1 gp41 only after gp41-express-
ing cells come in contact with cellular receptors, resulting in
association of 5-Helix on the surface of such cells. These results
strongly suggest that 5-Helix binds to the prehairpin interme-
diate of gp41 and that this intermediate is in an “open” confor-
mation that is accessible to inhibitory compounds.
EXPERIMENTAL PROCEDURES
Cloning and Mutagenesis—The plasmid pMMHa3Myc was used as
a template to amplify three tandem copies of the Myc epitope tag by
PCR with primers encoding both 5 and 3 NdeI sites (for N-terminally
tagged versions) and with primers encoding both 5 and 3 BamHI sites
(for C-terminally tagged versions). The amplified 120-base pair frag-
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ments were ligated into the p5-Helix plasmid to generate p3Myc/5-
Helix and p5-Helix/3Myc, respectively. Aspartate substitutions (V549D,
L556D, Q563D, and V570D) in p5-Helix/3Myc were introduced individ-
ually into the final (third) N40 segment by PCR to generate p5-He-
lix(D4)/3Myc. The p3Myc/6-Helix and p6-Helix/3Myc constructs were
prepared in the same manner as above by ligating the PCR products
into p6-Helix.
Protein Expression and Purification—All of the proteins were ex-
pressed in the Escherichia coli strain BL21(DE3)/pLysS using the T7
expression system (23). Overnight cultures (10 ml) were used to inocu-
late 1 liter of Luria Broth medium and grown to log phase at 37 °C.
Overproduction of the protein was induced by the addition of isopropyl
thio--D-galactoside to a final concentration of 1 mM. After 3 h of
induction, the cells were harvested and stored frozen (20 °C) until
purification. Bacterial pellets were resuspended in 50 mM Tris-HCl
buffer (pH 8.0) containing 100 mM NaCl, lysed by sonication, and
centrifuged (6,000  g for 30 min) to obtain an inclusion body fraction.
Each 5-Helix and 6-Helix variant was enriched in this fraction. The
pellets were resuspended in 100 mM Tris-HCl buffer (pH 8.0) containing
6 M guanidine hydrochloride, 10 mM imidazole, and 1 mM dithiothreitol.
After clarification by centrifugation (15,000  g for 15 min), the histi-
dine-tagged proteins were affinity-purified on nickel-nitrilotriacetate
(Qiagen) columns at room temperature. The proteins were eluted with
50 mM Tris-HCl buffer (pH 8.0) containing 6 M urea, 100 mM NaCl, and
100 mM imidazole. The eluted protein was refolded by dialyzing against
50 mM Tris-HCl (pH 8.0). After dialysis, all of the proteins were purified
to 95% purity by anion exchange chromatography on an A¨KTA Puri-
fier 10 (Amersham Biosciences), using a MonoQ column and a linear
gradient of NaCl (0–1 M). Protein concentrations were determined by
absorbance at 280 nm in 6 M guanidine hydrochloride (24).
CD Spectroscopy—CD measurements were performed in PBS (pH
7.4) with an Aviv 62DS CD spectrometer (Aviv Associates) equipped
with a thermoelectric temperature controller. Wavelength scans (200–
260 nm) were performed on 10 M protein solutions. Thermal denatur-
ation profiles were obtained by measuring the ellipticity at 222 nm
(222) as a function of temperature. Protein solutions (10 M) were
measured at 1-degree intervals starting at 4 °C, with an equilibration
time of 2 min and an acquisition time of 0.5 min. The apparent melting
temperature (Tm) was estimated from the maximum of the first deriv-
ative of 222 with respect to temperature. Because of the extreme ther-
mal stability of these proteins, these experiments were performed in
PBS in the presence of 3.7 M guanidine hydrochloride.
Tissue Culture—NIH3T3 and 293T cell lines were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 1% glutamine,
FIG. 1. HIV-1 gp41 structure and
5-Helix variant. a, a schematic view of
HIV-1 gp41, showing the location of the
fusion peptide (FP), the two hydrophobic
heptad repeat regions, the transmem-
brane segment (TM), and the cytoplasmic
region (cyto). The location of certain N-
and C-peptides are drawn above. b, a rib-
bon model of the N36/C34 complex (8),
which forms the core of the gp41 ectodo-
main, viewed looking from the side (left
panel) and down the 3-fold axis (right
panel). Molecular graphics were produced
using WebLab Viewer (Molecular Simula-
tions). c, a 5-Helix variant (5-Helix/3Myc)
that consists of three N40 segments
(gray), two C38 segments (blue), a His6
tag, and a 3Myc epitope tag (green). The
N40 to C38 junctions are joined with a
GGSGG linker, and the C38 to N40 junc-
tions are joined with a GSSGG linker. d, a
structural model of 5-Helix/3Myc based
on the known structure of the N36/C34
complex (8). Note that 5-Helix and its
variants lack the third C-peptide helix
and therefore bind to free C-peptide with
high affinity.
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1% penicillin-streptomycin, and 10% fetal calf serum or 10% bovine calf
serum, respectively, at 5% CO2 and 37 °C. Syncytia assays were per-
formed as described previously (15).
For the cell surface co-immunoprecipitation assays, 2 g of the HIV-1
envelope expression plasmid pCMVgp160 was transfected by the cal-
cium phosphate method into 2  105 293T cells/well in a six-well dish.
Two days after transfection, the 293T cells were incubated with 100 g
of each protein in the presence or absence of receptors (10 g of sCD4 or
3  106 target cells) at 37 °C for 1 h. The cells were then washed with
PBS (pH 7.4) and lysed with 1.5 ml of lysis buffer (50 mM Tris-HCl, pH
7.4, 150 mM NaCl, and 1% Triton X-100). The clarified supernatants
were incubated overnight (4 °C) with 25 l of Sepharose beads coupled
to the anti-Myc monoclonal antibody 9E10. After four washes with PBS,
the immunoprecipitates were separated by 10% SDS-polyacrylamide
gel electrophoresis and immunoblotted with the anti-gp41 monoclonal
antibody Chessie 8 (National Institutes of Health AIDS Research and
Reference Reagent Program), and a horseradish peroxidase-conjugated
anti-mouse IgG antibody (Jackson ImmunoResearch). To detect binding
of 5- or 6-Helix to the cells, the immunoprecipitates were separated on
a 12% SDS-polyacrylamide gel and immunoblotted with monoclonal
antibody 9E10. The sCD4 and target cell lines (3T3.T4, 3T3.T4.CCR5,
3T3.T4.CXCR4) were obtained from the National Institutes of Health
AIDS Research and Reference Reagent Program.
C34 Peptide Binding Assay—The C34 peptide precipitation experi-
ment was performed in 500 l of PBS (pH 7.4) with 10 M protein
(5-Helix or 6-Helix variants) and 10 M C34 peptide. The solution was
added to 25 l of anti-Myc beads and incubated at 4 °C for 1 h. After the
unbound supernatant was removed, the beads were washed four times
with 1.5 ml of PBS buffer. The bead-bound samples were analyzed by a
16.5% Tris-Tricine polyacrylamide gel (25) and immunoblotted with an
FIG. 2. Helical structure and ther-
mal stability of 5-Helix variants. a,
CD spectra of 5-Helix (Œ), 3Myc/5-Helix
(), and 5-Helix/3Myc (E) at 4 °C in PBS
(pH 7.4). b, thermal denaturation profiles
of 5-Helix (Œ), 3Myc/5-Helix (), and
5-Helix/3Myc (E) monitored by ellipticity
at 222 nm in PBS (pH 7.4) containing 3.7
M guanidine hydrochloride.
TABLE I
Biophysical data and inhibitory potency of 5- and 6-helix variants
CD scans were performed on 10 M protein solutions in PBS (pH 7.4).
For the 3Myc-tagged proteins, the residues of the epitope tag were
assumed to be nonhelical and were not included in calculating the
molar ellipticity at 222 nm (222). The apparent melting temperatures
(Tm) were estimated from thermal denaturation profiles of 222. Inhibi-
tion of cell-cell fusion was measured in a syncytium assay. The means
and standard errors were calculated from triplicate experiments.
Protein 222 Tm IC50
deg cm2/dmol °C M
5-Helix 28,900 98 0.015  0.002
3Myc/5-Helix 29,100 98 0.111  0.004
5-Helix/3Myc 29,100 98 0.046  0.003
5-Helix(D4)/3Myc 28,200 96 10
6-Helix 30,800 100 10
3Myc/6-Helix 30,500 100 10
6-Helix/3Myc 30,600 100 10
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anti-C34 polyclonal antibody and horseradish peroxidase-conjugated
anti-rabbit IgG antibody (Jackson ImmunoResearch).
RESULTS
Biophysical Characterization of 5- and 6-Helix Variants—To
use 5-Helix as a structural probe for gp41, we designed two
5-Helix variants containing three copies of the Myc epitope
(EQKLISEEDL) at either the N terminus (3Myc/5-Helix) or the
C terminus (5-Helix/3Myc; Fig. 1, c and d). As a negative
control, we constructed a Myc-tagged version of a mutant 5-He-
lix (5-Helix(D4)/3Myc) that contains a disruption of the C-
peptide-binding site and that was previously shown to be inef-
fective in inhibiting gp41-mediated fusion (19). We also
constructed N- and C-terminally Myc-tagged versions of 6-He-
lix (3Myc/6-Helix and 6-Helix/3Myc, respectively), a protein
that does not inhibit HIV-1 membrane fusion because the C-
peptide-binding site has been filled by an attached C-peptide.
Our two Myc-tagged versions of 5-Helix have biophysical
properties nearly identical to untagged 5-Helix (Table I and
Fig. 2). By CD analysis, all three proteins show CD spectra
with minima at 208 and 222 nm, as is typical for helical
proteins (Fig. 2a). The molar ellipticities at 222 nm for each of
these proteins were indistinguishable, indicating similar levels
of helicity (Table I). Moreover, the three proteins were highly
soluble (data not shown) and extremely stable, with a melting
temperature (Tm) of 98 °C in the presence of 3.7 M guanidine
hydrochloride in PBS (pH 7.4) (Table I and Fig. 2b). We thus
conclude that the Myc epitope tags do not affect the overall
helical structure and stability of 5-Helix protein. Likewise, the
biophysical properties of 6-Helix/3Myc and 3Myc/6-Helix were
nearly identical to untagged 6-Helix. Consistent with previous
results, the mutant construct 5-Helix(D4)/3Myc was slightly
less helical and less stable than wild-type 5-Helix (Table I) (19).
Inhibitory Activity of 5- and 6-Helix Variants—Both 3Myc/5-
Helix and 5-Helix/3Myc bound to synthetic C34 peptide in an
immunoprecipitation assay using the anti-Myc monoclonal an-
FIG. 3. C34 peptide binding assay of the 5- and 6-Helix vari-
ants. C34 peptide was mixed with the 5- and 6-Helix variants and
immunoprecipitated with an anti-Myc monoclonal antibody. Binding to
C34 peptide was determined by Western blot analysis with an anti-C34
polyclonal antibody.
FIG. 4. Cell surface co-immunopre-
cipitation of 5- and 6-Helix variants.
a, 293T cells transfected with gp160 were
incubated with 5-Helix (lanes 1–8) and
6-Helix (lanes 9–14) variants in the ab-
sence or presence of sCD4 and subjected
to cell surface co-immunoprecipitation
with the anti-Myc monoclonal antibody
9E10. Binding to gp41 was determined by
Western blot analysis with the gp41
monoclonal antibody Chessie 8. b, 293T
cells expressing gp160 were incubated
with 5-Helix/3Myc in the absence or in
the presence of retrovirally transduced
NIH3T3 cell lines that express cellular
receptors for HIV-1. Binding to gp41 was
determined as in a. In lanes 7–10, the
anti-CD4 monoclonal antibody Q4120
was added to the reactions to block CD4
interactions with gp120. The arrows indi-
cate the positions of gp41 and gp160. The
background band (*) at 80 kDa is unre-
lated to gp120/gp41, as explained in the
text.
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tibody 9E10 (Fig. 3, lanes 3 and 4). In contrast, the 5-Helix(D4)/
3Myc, 3Myc/6-Helix, and 6-Helix/3Myc proteins showed no C34
binding (lanes 5, 7, and 8).
Consistent with their C34 binding activity, both 3Myc/5-
Helix and 5-Helix/3Myc showed potent inhibitory activity
against cell-cell fusion mediated by HIV-1 envelope protein,
with half-maximal inhibition at 111 and 46 nM, respectively
(Table I). These values are 10- and 3-fold less potent than
that of untagged 5-Helix. The reduced potency of the tagged
proteins may be due to steric constraints in accessing the gp41
C-peptide region during the membrane fusion process. Fur-
thermore, these constraints may be more severe for 3Myc/5-
Helix, in which the 39 additional residues of the epitope tag are
expected to be oriented toward the viral membrane (see Fig. 6).
A reduction in inhibitory activity has also been observed for a
hemagglutinin epitope-tagged version of the C-peptide DP178
(5). In contrast to the inhibitory activity of the 5-Helix variants,
four different control proteins (5-Helix(D4)/3Myc, 6-Helix,
3Myc/6-Helix, and 6-Helix/3Myc) showed no detectable inhibi-
tory activity at the highest concentration tested (10 M).
Binding of Tagged 5-Helix to Activated gp41—The preserva-
tion of inhibitory activity in 3Myc/5-Helix and 5-Helix/3Myc
allowed us to explore the conditions under which 5-Helix binds
to gp41. Using a surface co-immunoprecipitation assay, we
investigated whether these proteins could bind to gp41 ex-
pressed on the surface of transfected 293T cells (Fig. 4a). 293T
cells were transfected with a HXB2 envelope expression plas-
mid, which directs expression of gp160, the precursor polypep-
tide that is proteolytically processed to generate the envelope
complex of gp120 and gp41 (26). 48 h after transfection, 293T
cells were incubated with the panel of 5-Helix and 6-Helix
variants in the presence or absence of sCD4. Binding of these
polypeptides to the surface of transfected cells was determined
by immunoprecipitation with the anti-Myc monoclonal anti-
body 9E10. Both 3Myc/5-Helix and 5-Helix/3Myc showed low
levels of gp41 binding in the absence of sCD4, and this binding
was greatly increased in the presence of sCD4 (lanes 4 and 6).
The specificity of this gp41 binding was shown by the lack of
binding by 5-Helix(D4)/3Myc, 3Myc/6-Helix, and 6-Helix/3Myc
(lanes 8, 12, and 14). Interestingly, a high molecular weight
FIG. 5. Cell surface localization of 5-
and 6-Helix variants. a, 293T cells
transfected with gp160 were incubated
with 5- (lanes 1–4) and 6-Helix (lanes 5
and 6) variants in the absence or presence
of sCD4 and subjected to cell surface im-
munoprecipitation with the anti-Myc
monoclonal antibody 9E10. Association of
the protein to the transfected cell surface
was determined by Western blot analysis
with the anti-Myc monoclonal antibody
9E10. b, 293T cells expressing gp160 were
incubated with 5-Helix/3Myc in the ab-
sence or in the presence of retrovirally
transduced NIH3T3 cell lines that ex-
press cellular receptors for HIV-1. Associ-
ation of the protein to the cell surface was
determined as in a. In lanes 7–10, the
anti-CD4 monoclonal antibody Q4120
was added to block CD4 interactions with
gp120. The positions of protein molecular
mass markers are indicated at the left.
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band, corresponding in size to uncleaved gp160, was also im-
munoprecipitated in a parallel pattern. Reprobing of the West-
ern blots with an anti-gp120 antibody confirmed that this band
was indeed gp160 (data not shown). Because the C-peptide
DP178 also has been shown to bind to receptor-activated gp160
(5), this result indicates that significant conformational
changes can be induced in the envelope protein even in the
absence of proteolytic processing. In these immunoprecipita-
tion experiments, we also detected an 80-kDa background band
whose identity is unknown. However, this band is unrelated to
HIV-1 envelope, because we also detect it in immunoprecipita-
tions from untransfected 293T cells (data not shown).
We further investigated whether surface-expressed cellular
receptors could similarly activate the binding of 5-Helix to
gp41. 293T cells expressing gp160 were incubated with 5-Helix/
3Myc in the presence of a panel of retrovirally transduced
NIH3T3 cell lines that express cellular receptors for HIV-1
(Fig. 4b). Whereas nonexpressing NIH3T3 cells showed no ef-
fect (compare lanes 1 and 2), cell lines expressing CD4 trig-
gered a large increase in binding of 5-Helix/3Myc to gp41 (lanes
4–6). The conformational changes allowing binding of 5-Helix/
3Myc appear to be largely induced by CD4, because the addi-
tional expression of CXCR4 (lane 6), the co-receptor for the
envelope protein (HXB2 strain) used in these studies, caused
only a slight increase in binding. In all cases, the binding of
gp41 by 5-Helix/3Myc was effectively inhibited by the mono-
clonal antibody Q4120 (lanes 7–10), which binds to CD4 and
blocks its binding by gp120. These results demonstrate that
5-Helix binds to a conformation of gp41 activated by interaction
of the envelope protein with cellular receptors.
Association of Tagged 5-Helix on the Surface of Transfected
293T Cells—To further characterize our surface immunopre-
cipitation experiments, we determined the levels of 5-Helix/
3Myc immunoprecipitated from the cell surface in the presence
and absence of receptors. Low levels of 5-Helix/3Myc were
precipitated in the absence of sCD4 (Fig. 5a, lane 1), but the
levels were dramatically increased in the presence of sCD4
(lane 2). In contrast, 5-Helix(D4)/3Myc and 6-Helix/3Myc
showed no precipitation either in the presence or absence of
sCD4 (lanes 3–6).
The level of 5-Helix/3Myc precipitated was not affected by
the addition of NIH3T3 cells lacking human HIV-1 receptors
(Fig. 5b, lanes 1 and 2). In contrast, the levels of precipitated
5-Helix/3myc were greatly enhanced by the addition of cell
lines expressing CD4 or CD4 and co-receptors (lanes 4–6). In
all cases, the immunoprecipitation of 5-Helix/3Myc was dras-
tically decreased by addition of the anti-CD4 antibody (Q4120)
(lanes 7–10), paralleling the trend seen in gp41 binding exper-
iments (Fig. 4b). Together these results show that interaction
of envelope protein to CD4 facilitates association of 5-Helix to
the cell surface.
DISCUSSION
Our results show that 5-Helix binds poorly to native gp41 but
well to gp41 activated by interaction of envelope protein with
cellular receptors. The fusogenic trimer-of-hairpins conforma-
tion is unlikely to be disrupted by 5-Helix, because this hairpin
structure involves extremely stable intramolecular interac-
tions (2). Consistent with this assumption, we find that 5-Helix
does not bind to recombinant 6-Helix, which mimics the trimer-
of-hairpins conformation of gp41.2 Therefore, our results
strongly suggest that the molecular target of 5-Helix is the
prehairpin intermediate, a prefusogenic conformation previ-
ously inferred from the inhibitory activity of C-peptides (2, 5).
Because this intermediate is a transiently populated species
during the membrane fusion process, it has been difficult to
determine its structure directly. The analysis of peptide inhib-
itors, however, provides important insights into its structural
features. The binding of the C-peptide DP178 to this interme-
diate suggests that it contains an exposed trimeric N-peptide
coiled coil that has not yet formed a six-helix structure with the
adjacent C-peptide region of gp41 (5). Interestingly, the N-
peptide N36Mut(e,g), which forms a homotrimer but cannot bind
the C-peptide region of gp41, is also a potent inhibitor of gp41-
mediated fusion (18). It remains to be shown directly that
N36Mut(e,g) binds to the prehairpin intermediate, but this ob-
servation raises the possibility that the trimeric N-peptide
region of the gp41 prehairpin intermediate undergoes a mono-
mer-trimer equilibrium (18, 27).
Our findings indicate that this prefusogenic conformation
also contains C-peptide regions that are exposed enough to
allow access of tagged 5-Helix, a 30-kDa protein. Although this
exposed C-peptide region almost certainly binds to the 5-Helix
protein as an -helix, we cannot exclude the possibility that it
exists in a different conformation in the prehairpin intermedi-
ate and is induced into a helical conformation by binding of
5-Helix. Taken together, these results provide a view of the
prehairpin intermediate as a largely open structure in which
both the N- and C-peptide regions are accessible and thus
vulnerable to binding by peptide inhibitors (Fig. 6).
Treatment of HIV-1 virions with sCD4 has been shown to
result in gp120 dissociation and the increased binding of sev-
eral gp41 monoclonal antibodies (4). This observation raises
the formal possibility that increased binding of 5-Helix to ac-
tivated gp41 may likewise reflect exposure of large regions of
gp41 because of gp120 shedding. However, we believe that the2 T. Koshiba and D. C. Chan, unpublished data.
FIG. 6. A model of HIV-1 membrane fusion and its inhibition. In
the native state (left panel) of the trimeric gp120/gp41 complex, the
fusion peptide is presumably buried in a hydrophobic pocket within the
envelope protein. Little is known about the structure of native gp41, but
our results show that the C-peptide region is partially exposed. Upon
interaction of gp120 with CD4 and co-receptors on the surface of target
cells, gp41 undergoes a conformational change to the prehairpin inter-
mediate state. This transient intermediate has a highly exposed, open
structure and is the target for C-peptide and 5-Helix inhibitors. In this
prefusogenic state, the N-peptide regions (gray) form an exposed trim-
eric coiled-coil. The C-peptide region (blue) is also exposed; it is either in
an -helical conformation or can be readily induced into such a confor-
mation by 5-Helix. We have drawn the prehairpin intermediate with
the fusion peptide inserted into the target membrane. However, it
should be noted that fusion peptide insertion is probably not essential
for exposure of either the N- or C-peptide regions, because binding of
DP178 (5) and 5-Helix (Fig. 4) to uncleaved gp160, in which the fusion
peptide is expected to be constrained, is activated by cellular receptors.
The prehairpin intermediate resolves to the fusion-active hairpin struc-
ture when the C peptide region binds to the N peptide trimeric coiled-
coil (right panel). The diagram was modified from Ref. 2.
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target of 5-Helix is likely to be a true fusion intermediate,
because binding leads to inactivation of gp41 fusion activity.
Furthermore, we find that sCD4 leads to increased binding of
5-Helix to uncleaved gp160 (Fig. 4), a result incompatible with
the view that gp120 shedding is responsible for 5-Helix
binding.
We find that low levels of gp41 binding are observed in the
absence of cellular receptors (Fig. 4, a, lanes 3 and 5, and b,
lanes 1 and 2), implying that the C-peptide region of gp41 is
only partially accessible in the absence of activation. This poor
accessibility in native gp41 may be due to steric constraints or
the adoption of an alternative conformation by the C-peptide
region. Alternatively, the low level detected may reflect meta-
stability of the native state of viral envelope proteins (28–30);
that is, a small fraction of gp41 molecules at a given time may
adopt a prehairpin-like conformation even in the absence of
cellular receptors. It is interesting to compare our results with
the finding that several monoclonal antibodies (2F5, 4E10, and
Z13) directed against the membrane proximal region of gp41
bind better to native gp41 than activated gp41 (31). The
epitopes recognized by these antibodies are located slightly
C-terminal to the end of the C-peptide, because the 2F5 epitope
spans residues 657–670 and the 4E10 epitope spans 671–676.
It is likely that these differences in binding preference reflect
different conformations recognized by 5-Helix versus the mono-
clonal antibodies. The study of these differences may reveal
structural changes in gp41 during the fusion process.
These insights into HIV-1 gp41-mediated membrane fusion
will likely also apply to the entry of many other enveloped
viruses that have fusion proteins with heptad repeats. Struc-
tural studies have revealed that members of the retrovirus,
orthomyxovirus, paramyxovirus, and filovirus families contain
fusion proteins with a trimer-of-hairpins structure (1, 32). Be-
yond these structural similarities, the paramyxovirus SV5 fu-
sion protein (F) has been shown to form a transient prehairpin
intermediate prior to fusion that can be inhibited by synthetic
peptides corresponding to the heptad repeats (33).
Finally, it should be noted that the N- and C-peptide regions
of the gp41 prefusogenic intermediate are highly conserved
among diverse HIV-1 strains (8, 19). Therefore, it is not sur-
prising that agents targeting these regions have broad neutral-
izing activity, although the emergence of inhibitor-resistant
strains remains a concern (34). Our results should facilitate the
development of HIV-1 entry inhibitors and may lead to new
vaccine strategies.
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